Xenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery
Dr.
Added Dr. Pimstone, “Dr. Empfield comes to us with a strong track record in both biotech and large pharmaceutical settings where he successfully identified and delivered multiple high quality drug candidates into development. At Xenon, Dr. Empfield is well-positioned to contribute to the strategic expansion of our pipeline. We remain focused on advancing a diverse product portfolio through partnered programs that address large therapeutic markets and through our own proprietary product candidates that address rare diseases.”
Prior to joining Xenon, Dr. Empfield served as Vice President, Drug Discovery and Chemistry; Co-Head of Research,
In addition to Dr. Empfield joining the Company on a full-time basis, Dr.
About
Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics®, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon's Extreme Genetics® platform has yielded the first approved gene therapy product in the
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding our management and prospects, the growth of our research and development organization and product candidate pipeline and the progress and potential of our pipeline and ongoing development programs. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; our Extreme Genetics® discovery platform or ongoing collaborations may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones pursuant to our collaboration agreements; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the
“Xenon,” the Xenon logo, and “Extreme Genetics” are registered trademarks or trademarks of
Investor/Media Contact:Jodi Regts Senior Director, Corporate AffairsXenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: investors@xenon-pharma.com